No problem with Agouron; it is just like Ligand in fast forward, or MLNM from 19 to 12-13, etc, etc. Live by the sword, die by the sword, ...
No kidding about low cost (AEM), and I guess I confused Stillwater with Tidewater.
Back to topic, I found a little article on this pharmacogenomics area, the subtitle is "New, hot - but there is no it - yet" Cute, eh.
Says genomics companies are looking to access the expertises of CROs (Contract Research Organizations), HMOs and hospital centers in order to make p-genomics work. P-genomics deals in 96/97 include those by Abbott and Frenh company Genset; the SmithKline-Incyte deal, the Spectra acquisition by Glaxo, deals by AFFX with Glaxo and with Oncormed, etc. Other firms listed as thinking that they can make a business in p-genomics are GENE, MLNM, and SQNA, and start-ups like Genaissance Pharmaceuticals and Nova Molecular. Another interesting start-up is Rosetta Inpharmatics out of Lee Hood's lab in U. Washington (Hood's technology was key for Applied Biosystems, now a unit of Perkin Elmer).
Overall pretty interesting stuff, but still some years away.
PB |
